@inproceedings{inproceedings, title  = {{Dupilumab provides long-term efficacy over 2.5 years in adults with moderate-to-severe atopic dermatitis}},

 url = {{}},

 year = {{2022}},

 month = {{1}},

 author = {{Cork M and Beck L and Bissonnette R and Wollenberg A and Simpson E and Praestgaard A and Aamodt K and Rossi A}},

 volume = {{187}},

 journal = {{BRITISH JOURNAL OF DERMATOLOGY}},

 pages = {{69-69}},

 note = {{Accessed on 2024/12/22}}}